Cancer Gene Therapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028, Segmented by Therapy (Oncolytic Virotherapy, Gene Induced Immunotherapy, Gene Transfer, and Others), By Indication (Breast Cancer, Ovarian Cancer, Lung Cancer, Liver Cancer, Pancreatic Cancer, Prostate Cancer, and Others), By End User (Biotechnology & Pharmaceutical Companies, Academic & Researc
Published Date: November - 2024 | Publisher: MIR | No of Pages: 320 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationCancer Gene Therapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028, Segmented by Therapy (Oncolytic Virotherapy, Gene Induced Immunotherapy, Gene Transfer, and Others), By Indication (Breast Cancer, Ovarian Cancer, Lung Cancer, Liver Cancer, Pancreatic Cancer, Prostate Cancer, and Others), By End User (Biotechnology & Pharmaceutical Companies, Academic & Researc
In 2022, an estimated 66,470 people (48,520 men and 17,950 women) will be diagnosed with head and neck cancer in the United States.
Increasing research and development activities
In 2020, an estimated 276,480 new cases of invasive breast cancer will be diagnosed in women in the U.S. as well as 48,530 new cases of non-invasive (in situ) breast cancer.
Growing advancement in gene therapy
In march 2022, the National Heart Lung and Blood Institute granted USD 12 million to an Indiana University School of Medicine Researcher. This grant is for developing a major part of a gene therapy approach to safer and potentially curative treatments for hemophilia diseases.
Recent Development
- In Sept 2021, Adaptimmune collaborated with Genentech to develop allogeneic cell therapies indicated for the treatment of multiple cancers.
- In June 2021, Eisai and Bristol Myers Squibb agreed to partnered for the development and commercialization of Eisai's ADC, MORAb-202, for the treatment of advanced solid malignancies.
- In June 2021, GSK and iTeos Therapeutics partnered for developing EOS-448, an anti-TIGIT monoclonal antibody that had previously been approved in phase 1 for treatment of advanced solid malignancies.
- LuxturnaIn 2018, Spark Therapeutics launched Luxturna, a gene therapy for the treatment of inherited retinal diseases caused by mutations in a specific gene. Luxturna was the first gene therapy approved by the FDA for a genetic disease and has shown significant clinical benefit in patients.
- ZolgensmaIn 2019, Novartis launched Zolgensma, a gene therapy for the treatment of spinal muscular atrophy (SMA), a rare genetic disease that affects muscle strength and movement. Zolgensma is a one-time infusion that has shown significant clinical benefit in clinical trials and has been hailed as a breakthrough therapy.
- TecartusIn 2020, Kite Pharma, a Gilead Company, launched Tecartus, a CAR T-cell therapy for the treatment of mantle cell lymphoma. Tecartus has shown promising results in clinical trials and was granted accelerated approval by the FDA in 2020.
Market Segmentation
The Global Cancer Gene Therapy Market can be segmented by therapy, indication, end user and by region. Based on therapy, the market can be segmented into Oncolytic Virotherapy, Gene Induced Immunotherapy, Gene Transfer, and Others. Based on indication, the market can be segmented into Breast Cancer, Ovarian Cancer, Lung Cancer, Liver Cancer, Pancreatic Cancer, Prostate Cancer, and Others. Based on end user, the market can be differentiated Biotechnology & Pharmaceutical Companies, Academic & Research Institutions, and Others. Regionally, North America dominates the market among Asia Pacific, Europe, Middle East & Africa, and South America. Amongst the different countries, United States dominate the global cancer gene therapy market on account of growing demand for advanced therapy with low cost for curing the cancer diseases in the country.
Market Players
Abeona Therapeutics Inc., Asklepios BioPharmaceutical Inc., Altor Bioscience Inc., Bluebird bio-Inc., BioCancell Inc., Celgene Inc., Elevate Bio Inc., GlaxoSmithKline Inc., Genelux Corporation, Introgen Therapeutics Inc., OncoGenex Pharmaceuticals Inc., Merck KGaA are some of the leading players operating in the Global Cancer Gene Therapy Market.
| Attribute | Details |
| Base Year | 2022 |
| Historic Data | 2018 – 2021 |
| Estimated Year | 2023 |
| Forecast Period | 2024 – 2028 |
| Quantitative Units | Revenue in USD Million, and CAGR for 2018-2022 and 2023-2028 |
| Report Coverage | Revenue forecast, company share, competitive landscape, growth factors, and trends |
| Segments Covered | · By Therapy · By Indication · By End User · By Region |
| Regional scope | North America; Europe; Asia Pacific; South America; Middle East & Africa |
| Country scope | United States; Canada; Mexico; France; Germany; United Kingdom; Italy; Spain; China; India; Japan; South Korea; Australia; Brazil; Argentina; Colombia; South Africa; Saudi Arabia; UAE |
| Key companies profiled | Abeona Therapeutics Inc., Asklepios BioPharmaceutical Inc., Altor Bioscience Inc., Bluebird bio-Inc., BioCancell Inc., Celgene Inc., Elevate Bio Inc., GlaxoSmithKline Inc., Genelux Corporation, Introgen Therapeutics Inc., OncoGenex Pharmaceuticals Inc., Merck KGaA |
| Customization scope | 10% free report customization with purchase. Addition or alteration to country, regional & segment scope. |
| Pricing and purchase options | Avail customized purchase options to meet your exact research needs. Explore purchase options |
| Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy